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Sudden cardiac death is a significant cause of mortality in the United States, with an 
estimated 400,000 cases per year (1 1). Discovery of an effective antiarrhythmic drug 
capable of reducing the incidence of sudden cardiac death by as little as 10% would result 
in the saving of approximately 40,000 lives annually. Obviously, there is a need for an 
effective form of therapy capable of safely treating patients at risk of sudden cardiac 
death. The Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that antiarrhyth- 
mic therapy that successfully prevented asymptomatic and mildly symptomatic ventricular 
arrhythmias in post-myocardial infarction patients was associated with an increased risk 
of sudden cardiac death (32). Iatrogenic death is untenable and, therefore, an active search 
is underway for an antiarrhythmic drug that prevents (ideally), or reduces the probability 
of (at least), ventricular fibrillation or sudden cardiac death. Since certain currently 
available antiarrhythmic drugs (i.e., flecainide, encainide, and ethmozine) have proven to 
be inefficacious against sudden cardiac death (32), several antiarrhythmic drugs are cur- 
rently under development. According to the Vaughan-Williams classification scheme, 
class I11 antiarrhythmic drugs increase the refractory period via an increase in the action 
potential duration, without altering the maximal rate of depolarization (33). Such an 
electrophysiologic mechanism may be ideal for the prevention of re-entrant arrhythmias, 
which constitute the predominant mechanism for life-threatening arrhythmias in humans 
(4). This review focuses on the recently developed class I11 drug, UK-68,798, a potent 
and efficacious antiarrhythmic agent with antifibrillatory properties. The review will 
discuss the chemistry, in vitro and in vivo cardiovascular pharmacology, mechanism of 
action, and pharmacokinetics of UK-68,798. 
CHEMISTRY 
The chemical name of UK-68,798 is l-(4-methanesulfonamidophenoxy)-2-[N-4- 
methanesulfonamidophenethyl)-N-methylamine]ethane. The structure of the drug is 
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shown in Fig. 1.  The molecular weight of the free base of UK-68,798 is 441.6 g/mol and 
the empirical formula is C,9H2,N,0,S2 (7). For in vivo administration, UK-68,798 is 
freely soluble in dilute acid (HC1) media (acidified saline) (3,7). UK-68,798 is a weak 
acid (due to methanesulfonamido protons, with a pK, of 9.0 and 9.6) and a moderate base 
(pK, of 7.0), and at physiologic pH the sulfonamido groups are 2.45 and 0.63% ionized 
and the amine is 28.5% ionized (3). The melting point of the drug is 147-149°C (3). 
Structurally, the two methanesulfonamide functional groups at the terminal poles of the 
near-symmetric molecule are fundamentally important for the expression of class I11 
antiarrhythmic activity (12). The methanesulfonamide functional group is a commonality 
among several relatively new compounds with demonstrated class I11 antiarrhythmic 
activity. Drugs with class I11 antiarrhythmic activity that possess the methanesulfonamide 
functional group include E-403 1, sematilide, CK-3579, and d-sotalol (5,18). 
PHARMACOLOGY 
The cardiovascular pharmacology of UK-68,798 has been studied using both in vitro 
and in vivo experimental and clinical paradigms. These studies have defined the electro- 
physiologic effects of UK-68,798, which classify it as a class 111 antiarrhythmic drug 
according to the Vaughan-Williams classification scheme (33). 
In Vitro Studies 
The in vitro pharmacology of UK-68,798 was investigated using a variety of cardiac 
tissue and cell preparations, including myocardial trabeculae, papillary muscle, isolated 
Purkinje fibers, and isolated ventricular myocytes. Of the numerous electrophysiologic 
determinations made using in vitro preparations, an unequivocal finding is that the cardiac 
action potential duration is prolonged by UK-68,798. In guinea pig isolated papillary 
muscle, stimulated at a frequency of 1 Hz, and at concentrations of lo-* through 10K6 
M, UK-68,798 increased the action potential duration (APD) by 21-58% (31). Prolon- 
gation of the APD by UK-68,798 has been confirmed in canine isolated left ventricular 
trabecular muscle (12). In the canine preparation, UK-68,798 prolonged the APD at 
concentrations as low as 5 nM, and dose-dependently increased the APD to a maximal 
prolongation at 2 pM. Both the APD,, (APD at 50% repolarization) and APD, (APD at 
90% repolarization) were increased by UK-68,798. The electrophysiologic effects of UK- 
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FIG. 1. Chemical structure of UK-68,798 
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68,798 were selective, as the drug was without effect on the resting membrane potential, 
action potential amplitude, or the maximal rate of phase 0 depolarization (Vma) in the 
canine trabecular preparation; the drug had selective class 111 activity. UK-68,798 had 
similar electrophysiologic effects on the APD in isolated ventricular Purkinje fibers. 
Purkinje fibers were more sensitive to the effects of UK-68,798 than ventricular muscle. 
Concentrations as low as 1 nM prolonged the APD in Purkinje fibers, with maximal APD 
prolongation observed at 500 nM (12,17). The EC50 values for the effect of UK-68,798 
on the APD,, in cardiac ventricular tissue and Purkinje fibers were 30 ? 10 and 5.3  2 
1.4 nM, respectively, indicative of the greater sensitivity of the Purkinje fiber to the 
APD-prolonging effect of the drug (12). Others have confirmed the sensitivity of the 
Purkinje fiber to the APD-prolonging effect of UK-68,798, as the estimated EC,, for the 
APD, in an isolated canine Purkinje fiber preparation was 5.5 f 0.9 nM (17). 
The effective refractory period (EM) of in vitro cardiac preparations was increased by 
UK-68,798. In guinea pig isolated papillary muscle stimulated at a frequency of either 1 
or 5 Hz, UK-68,798 increased the ERP at concentrations of 5-1,OOO nM (14). The 
increase in ERP was less at a stimulation rate of 5 Hz compared to 1 Hz. The conduction 
velocity was unaltered by UK-68,798 (12). The effect of UK-68,798 on the ERP of 
guinea pig isolated papillary muscle has been confirmed at concentrations of 10 nM to 1 
In addition to its electrophysiologic actions, UK-68,798 has negative chronotropic 
activity in vitro. In spontaneously beating guinea pig right atria, UK-68,798 dose- 
dependently reduced the rate of contraction (31,36). The negative chronotropic action of 
UK-68,798 in the atrial preparation was manifest at concentrations of lo-’ M and above 
(up to l ow5  M). The negative chronotropic effect of UK-68,798 was independent of 
P-adrenergic receptor blocking activity, as the dose-response curve to isoproterenol was 
not shifted to the left (the pD, value for the isoproterenol dose-response curve remained 
unaltered by UK-68,798) (36). However, the maximal chronotropic response to isopro- 
terenol was attenuated by UK-68,798 to a value of 71 * 6% of the maximum at a 
concentration of lop5 M. The effect is indicative of noncompetitive inhibition. In contrast 
to the effect of UK-68,798, propranoloi shifted the isoproterenol dose-response curve to 
the right (pD, value reduced), providing evidence that the atrial muscle paradigm dis- 
criminated P-adrenergic receptor antagonism. 
Class III antiarrhythmic agents increase the APD without affecting the maximal rate of 
phase 0 depolarization (33). The cellular mechanism for class I11 antiarrhythmic activity 
may be an increase in inwardly directed currents (i.e., current flux through sodium 
channels), as with the sea anemone polypeptide ATX I1 (24), or inhibition of outwardly 
directed currents (i.e., current flux through potassium channels) as with amiodarone 
(1,29) and E-403 1 (lo). The electrophysiologic mechanism by which UK-68,798 exerts 
its class 111 effects is similar to other class I11 agents and related to the latter of these two 
possible mechanisms. There are a number of potassium channels with which the class 111 
antiarrhythmic drugs may interact. Seven different potassium channels have been de- 
scribed in myocardial tissue and each may play a greater or lesser role in repolarization 
of the cell membrane. In guinea pig isolated ventricular myocytes, whole cell patch- 
clamp analysis has shown that UK-68,798 blocks a component of the delayed rectifier 
current (12). The delayed rectifier current is a function of two separate components, the 
“rapid” component (Ih), which is time independent, and the “slow” component (Iks), 
w (31). 
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which is time dependent (6,12). UK-68,798 blocks the “slow,” time-dependent potas- 
sium current (Iks) in guinea pig ventricular myocytes (12). The drug reduced the amplitude 
of the repolarizing I,, at a concentration of 50 nM and effectively blocked the current at 
a concentration of 2 pN. Therefore, the cellular mechanism by which UK-68,798 pro- 
longs the APD and increases the ventricular refractory period is through antagonism of the 
“slow” component of the delayed rectifier current. 
In Vivo Studies 
The cardiovascular effects of UK-68,798 have been investigated using in vivo exper- 
imental paradigms. The canine species is the most frequently studied to date. In accord 
with results of in vitro studies, UK-68,798 exhibits class I11 antiarrhythmic activity in 
both conscious and unconscious in vivo preparations (3,8,14,37). The drug has been 
studied to a limited extent in humans. 
The in vivo effect of UK-68,798 on electrocardiographic intervals provides evidence of 
its class I11 antiarrhythmic activity. In conscious and unconscious canines with a previous, 
surgically induced, anterior myocardial infarction, UK-68,798 prolonged the QT, interval 
(2) [Bazett’s corrected QT interval = QT interval in s/(R-R interval in ms)’/z] and 
increased the ventricular ERP (3,8,14,37). As the QT, interval approximates the ventric- 
ular APD, these data support the in vitro studies of APD prolongation by UK-68,798. A 
summary of the electrocardiographic effects of UK-68,798 from in vivo experimental 
studies is shown in Table 1. In conscious animals, UK-68,798 increased the ventricular 
ERP by a mean value of 27 ms (3). In the conscious canine preparation, the relative 
refractory period determined in the region of the anterior myocardial infarct was increased 
by UK-68,798 administration (169 * 6 ms predrug vs. 186 * 7 ms postdrug), and the 
ERP of the normal, noninfarcted myocardium also was increased (154 -+ 12 ms predrug 
vs. 170 ? 11 ms postdrug) (3). Similarly, in an unconscious canine preparation, UK- 
68,798 increased the ERP with electrical stimulation from the normal, noninfarcted myo- 
cardium by mean values of 24 and 20 ms (when paced at cycle lengths of 300 and 250 ms, 
respectively) (37). With electrical stimulation from the peri-infarct region, UK-68,798 
increased the ERP by a mean value of 23 ms (heart paced at cycle lengths of 300 and 250 
ms) (37). The in vivo effects of UK-68,798 on the ventricular ERP in the unconscious 
canine was associated with lengthening of the ERP in the epicardial region surrounding 
the infarcted myocardium (37). The magnitude of UK-68,798-mediated alterations of the 
ventricular ERP was similar to those reported for other class I11 drugs (5,18,19,21). The 
ventricular ERP was increased by 19, 30, and 24 ms by CK-3579, sematilide, and 
E-403 1, respectively (5,lS). Therefore, the electrocardiographic effects of UK-68,798 are 
in accord with changes induced by other class 111 antiarrhythmic drugs such as CK 3579 
and sematilide ( 9 ,  E-4031 (18), d,l-sotalol (19), and amiodarone (21). 
In conscious canines, UK-68,798 did not affect electrocardiographic intervals indica- 
tive of intracardiac conduction. The P-R interval and QRS duration were not influenced 
by UK-68,798 administration (3). The drug did not influence activation delay or conduc- 
tion times determined in discrete, localized regions of normal, noninfarcted myocardium 
and infarcted myocardium (3). The lack of an effect of UK-68,798 on electrocardio- 
graphic indices of intracardiac conduction velocity has been confirmed by others both in 
conscious and anesthetized dogs, as P-Q, e R ,  and QRS intervals were unaffected by the 
drug (8,37). 
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Although a significant number of patients succumb to sudden cardiac death annually, 
determination of patients at risk remains somewhat problematic. For certain forms of heart 
disease, programmed electrical stimulation (PES) testing is a reliable method of identi- 
fying at-risk patients. In patients with a previous myocardial infarction, PES-induced 
ventricular tachycardia is the single best predictor of spontaneous ventricular tachycardia 
and sudden death (26). The ability of a drug to suppress PES-induced arrhythmias has 
been suggested as being indicative of a better prognosis for therapeutic success (25); 
however, others have provided evidence to the contrary (16). The prognostic value of PES 
testing is dependent upon several factors including the presence or absence of underlying 
cardiac disease, the form of the underlying disease (coronary artery disease, idiopathic 
cardiomyopathy, or ischemic heart disease), the type of induced tachycardia (sustained or 
nonsustained), and the presence of spontaneous ventricular arrhythmias, among other 
factors. PES testing is used clinically to determine patient response to antiarrhythmic drug 
therapy. PES testing may not predict uniformly the long-term clinical response to a given 
antiarrhythmic drug, as evidenced by the data in the CAST report (32). PES testing failed 
to predict long-term antifibrillatory efficacy. Despite this limitation, PES testing remains 
an applicable method of characterizing the putative antiarrhythmic efficacy of a drug. This 
should not be construed as being synonymous with antifibrillatory activity. 
The antiarrhythmic efficacy of UK-68,798 has been studied in both unconscious and 
conscious canine preparations. In pentobarbital-anesthetized open chest dogs, PES- 
induced a sustained ventricular tachycardia 5 to 8 days after anterior wall myocardial 
infarction. The induction of the arrhythmia by PES was prevented by UK-68,798 (30 
kg/kg) (37). The cycle length of the induced tachycardia, in the animals that remained 
inducible after UK-68,798 administration, was increased from 166 to 222 ms (37). In a 
conscious canine preparation with a previous anterior wall myocardial infarction, UK- 
68,798 (900 pg/kg) reduced the incidence of PES-induced ventricular arrhythmias by 
50%, an incidence significantly lower than predrug inducibility (3). In the animals that 
remained inducible after UK-68,798 administration, the cycle length of the induced 
tachyarrhythmia was increased from 171 * 23 to 201 2 19 ms (3). Other class I11 drugs, 
such as sematilide, E-403 1, d,l-sotalol, and bretylium, have protected against PES- 
induced ventricular tachycardia by 58 to 100% (18,19,22). 
UK-68,798 possesses antiarrhythmic effects as determined by prevention of PES- 
induced ventricular tachyarrhythmias. The antifibrillatory properties of UK-68,798 have 
been studied using conscious and unconscious in vivo preparations. UK-68,798 was 
effective in significantly reducing the incidence of ventricular fibrillation in a conscious 
canine model of sudden coronary death (Fig. 2) (3). The model is one in which a previous 
anterior wall myocardial infarction results in a predictive, direct relationship between 
baseline inducible ventricular tachyarrhythmias and susceptibility to the development of 
lethal arrhythmias in response to a superimposed ischemic event in a region remote from 
the infarct-related artery (23,35). Sudden cardiac death, in the experimental model, was 
defined as death due to ventricular fibrillation within 1 h from the onset of posterolateral 
ischemia. Electrocardiographic evidence of regional ischemia (onset of ischemia) was 
manifested by ST-segment change and often associated with the appearance of coupled 
ventricular ectopic complexes. In the sudden death model, superimposition of an ischemic 
episode in a region remote from the infarct-related vessel results in ventricular fibrillation 
within 1 h from the onset of regional myocardial ischemia in the absence of an effective 
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FIG. 2. Survival rates of UK-68,798- and saline vehicle-treated animals subsequent to the development of 
posterolateral ischemia following left circumflex intimal injury. At 1 h after the development of posterolateral 
ischemia in the presence of an anterior myocardial infarct, UK-68,798 increased survival compared to saline 
vehicle-treated control animals. Data from ref. 3. 
antifibrillatory drug (see “control” data of Fig. 2) (23,35). Therefore, the critical time 
period (when ventricular fibrillation is most probable) is the first 60 min after the onset of 
ischemia, as opposed to a later time point when delayed death due to “pump failure” is 
the most likely cause of death. As shown in Fig. 2, the survival from sudden death was 
17% in control vehicle-treated animals, while in the UK-68,798 treated animals, survival 
was 67%. The antifibrillatory effect of UK-68,798 in the conscious canine model of 
sudden cardiac death is in accord with results obtained with other class 111 antiarrhythmic 
drugs such as CK3579, sematilide ( 5 ) ,  E-4031 (20), d,l-sotalol (19), and amiodarone 
(21), in which the incidence of ventricular fibrillation, or sudden cardiac death, was 
reduced significantly when compared to a vehicle-treated control group. A beneficial 
effect of UK-68,798 against ventricular fibrillation is not unequivocal, however, as others 
have failed to demonstrate an antifibrillatory effect of UK-68,798. In an unconscious open 
chest canine model with a previous myocardial infarction, UK-68,798 did not protect 
against the incidence of ventricular fibrillation in response to PES testing (37). The latter 
study differed from that which showed a protective effect in two respects: (i) ventricular 
fibrillation was induced by PES testing, not ischemia (a putatively re-entrant mechanism), 
and (ii) the effective antifibrillatory dose of UK-68,798 [900 pg/kg (3)] was higher than 
the doses used in the anesthetized dog studies (30 pglkg) (37). Preliminary studies with 
the conscious canine model, however, did not demonstrate protection against sudden 
death (ventricular fibrillation) at doses of 0.10 or 0.50 mgkg of UK-68,798 (L. Chi, 
personal communication). It remains to be determined whether significant antifibrillatory 
effects of UK-68,798 can be demonstrated at a dose less than 900 pg/kg, in the dosage 
range where antiarrhythmic efficacy has been demonstrated. The dose of UK-68,798 
effective against ventricular fibrillation may be greater than that required to attenuate the 
development of PES-induced ventricular tachyarrhythmias. A salutary action of UK- 
68,798 against ventricular fibrillation is supported by data demonstrating that the drug 
reduced the dispersion of depolarization caused by rapid pacing (13), an effect that may 
contribute to the antifibrillatory properties of the drug. In view of the results of CAST, the 
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reduction in sudden cardiac death due to ventricular fibrillation associated with UK- 
68,798 treatment in the conscious canine model may be a highly relevant end point in the 
preclinical evaluation of this drug rather than its ability to prevent PES-induced ventric- 
ular tachyarrhythmias. 
The precise electrophysiologic or pharmacologic mechanism for the antifibrillatory 
action of UK-68,798 in conscious animals has not been determined. However, a reduction 
in the dispersion of depolarization, possibly through prolongation of the APD or ERP, 
likely contributes in this regard. In conscious animal studies, in which the antifibrillatory 
effect of UK-68,798 was manifested during the development of a second myocardial 
infarction (ischemia-induced ventricular fibrillation), UK-68,798 did not influence the 
posterolateral wall infarct size (i.e., the size of the infarct developing subsequent to the 
onset of posterolateral ischemia), the time to the onset of posterolateral ischemia, or 
thrombus mass (3). Thus, the antifibrillatory action was not mediated through some 
indirect pharmacologic effect of the drug upon the processes leading to myocardial isch- 
emia and infarction. 
It has been suggested that the APD-prolonging effect of class I11 antiarrhythmic drugs 
may be inherently proarrhythmic (15). This suggestion derived from the view that the 
APD-prolonging effect of class I11 agents such as sotalol (30) and N-acetylprocainamide 
(9) exhibit reverse use dependence. Reverse use dependence implies that the magnitude 
of APD prolongation by class I11 agents is greater at slower heart rates than at faster heart 
rates (15). Thus, drugs with class I11 effects that maximally prolong the QT interval 
during bradycardia, or after a long diastolic interval (i.e., after an ectopic ventricular 
depolarization), may be associated with the development of torsades de pointes arrhyth- 
mias (27). Additionally, the intrinsic antiarrhythmic efficacy of class I11 agents may be 
limited because prolongation of the APD is of a lesser degree at higher heart rates when 
tachycardias are likely to develop, and drug efficacy is of greater importance. Since the 
APD-prolonging effect of UK-68,798 has been shown to be rate dependent in an isolated 
canine Purkinje fiber preparation [the degree of APD prolongation increased with increas- 
ing cycle length (17)], the in vivo administration of UK-68,798 may be associated with 
the development of arrhythmias due to excessive QT prolongation. Studies in the anes- 
thetized dog, however, revealed that UK-68,798 increased the ERP to a similar extent at 
pacing cycle lengths of 300 and 250 ms. The results indicate that the efficacy of the drug 
was preserved at the higher pacing rate. This in vivo effect remains to be confirmed. 
Experimental and clinical evidence regarding the efficacy of class I11 agents, in general, 
indicates that concern for the possible drug-induced torsades de pointes and the potentially 
inherent inefficacy of the class 111 agents at higher heart rates may not be warranted. For 
example, under experimental conditions in the postinfarcted canine heart, the class I11 
agents amiodarone, sematilide (5), and E-4031 (18) decrease the incidence of PES- 
induced ventricular tachyarrhythmias. Similarly, UK-68,798 reduces the incidence of 
PES-induced tachyarrhythmias in the canine heart after surgical induction of an anterior 
myocardial infarction (3,37). Additionally, UK-68,798 reduced the cycle length of the 
induced tachycardia in dogs that remained inducible after drug administration [the cycle 
length of the induced tachycardia increased from 171 _+ 23 ms before drug to 201 f 19 
ms after drug (3)]. These results to date suggest that UK-68,798 may be an effective class 
111 antiarrhythmic drug. Large clinical trials in humans will determine whether the po- 
tential for drug-induced torsades de pointes will negatively affect the therapeutic useful- 
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ness of UK-68,798, and whether the risk of this arrhythmia will be offset by antiarrhyth- 
mic and/or antifibrillatory efficacy of UK-68,798. 
The effects of UK-68,798 on the in vivo heart rate are somewhat variable as increases 
and decreases in the intrinsic heart rate after drug administration have been reported. 
When studied in anesthetized dogs, UK-68,798, at doses in the 5-100 pglkg range, 
decreased the heart rate by 36 ? 6 beatslmin from a baseline of 148 * 8 beatslmin at 100 
pg/kg only (14). At a dose of 30 pg/kg, UK-68,798 reduced the heart rate in an uncon- 
scious canine preparation (159 2 19 beats/min predrug vs. 143 2 14 beatslmin postdrug, 
mean 2 SEM) (37). The influence of UK-68,798 upon the heart rate may depend on the 
central nervous system status of the animal, since in conscious dogs the heart rate changed 
to a lesser degree. At a dose of 100 pg/kg, the drug maximally reduced the heart rate by 
only 12 beats/min (8), and at a dose of 900 pglkg, UK-68,798 did not change the heart 
rate (3). In human patients, the drug did not affect the heart rate at doses of 1.5, 3.0, and 
4.5 pglkg (28). 
Data on the effects of UK-68,798 in humans are limited. In patients with coronary 
artery disease, UK-68,798 at intravenous doses of 1.5, 3.0, and 4.5 p g k g  increased the 
QT, interval by 41,40, and 81 ms and the uncorrected QT interval by 36, 52, and 83 ms, 
respectively (28). UK-68,798 did not affect the heart rate, blood pressure, PR interval, or 
QRS complex duration in the clinical population studied (28). The drug was reported to 
be well tolerated with no significant adverse effects (28). These preliminary data suggest 
that UK-68,798 exhibits class I11 antiarrhythmic activity in humans and is without po- 
tentially limiting adverse drug effects. The results of a chronic dosing schedule will 
provide important information regarding the longer-term consequences of exposure to the 
drug. 
ADVERSE EFFECTS 
In view of the results from CAST, the adverse effect profile of potential antiarrhythmic 
andlor antifibrillatory drugs is of considerable importance. In this regard, adverse effects 
attributable to UK-68,798 are limited due to the lack of available data. As indicated 
above, preliminary data suggest a favorable profile for the drug (28). Experimentally, 
studies of the antiarrhythmic properties of UK-68,798 have indicated that the drug may 
have proarrhythmic effects. In an in vitro study on the guinea pig isolated papillary 
muscle, early afterdepolarizations were observed in 2/I I (18%) preparations (31). In a 
conscious canine preparation, administration of UK-68,798 at a dose of 900 pglkg was 
associated with the appearance of spontaneous, transient ectopic ventricular complexes in 
58% of the treated animals (3). These arrhythmias did not precipitate more serious rhythm 
disturbances (sustained or nonsustained ventricular tachycardia, or ventricular fibrilla- 
tion), and dissipated 60 min after drug administration. Although limited in scope, these 
adverse effects (proarrhythmic) indicate that the drug has the potential to exacerbate or 
induce ventricular arrhythmias. It remains to be determined whether such arrhythmias will 
be manifest under clinical circumstances in patients receiving the drug. 
PHARMACOKINETICS 
The pharmacokinetic profile of UK-68,798 has been determined in dogs, normal hu- 
man volunteers, and patients with coronary artery disease. In the dog, the terminal 
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elimination half-life of UK-68,798 was 4-6 h (0.254). 167 h- '), the volume of distri- 
bution was 4.0 L, and the clearance rate was 1.2 ml/min/kg (7). The oral bioavailability 
of UK-68,98 in the dog was determined to be between 72 and 100% (7). In human 
volunteers, after a 10 pgkg intravenous dose of UK-68,798, plasma levels of the drug 
declined in a biexponential manner with a termination half-life of 0.075 h-' (34). After 
a 10 Fg/kg oral dose of UK-68,798, the peak plasma concentration was 2.5 ng/ml at 3 h 
after receiving the drug, and the terminal elimination half-life was 0.081 h- '  (34). 
Forty-eight hours after an intravenous or oral dose of UK-68,798 (10 pgkg), the plasma 
concentration was 0.05-0.12 ng/ml (34). In patients with coronary artery disease, UK- 
68,798 exhibited first-order kinetics with a mean clearance rate of 4.7 * 1.2 mliminikg, 
and a terminal elimination half-life of 9.7 h (0.103 h-') (28). 
SUMMARY 
This review examined the currently available but limited data regarding the antiarrhyth- 
mic and antifibrillatory actions of UK-68,798. The drug is a potent and efficacious class 
I11 antiarrhythmic agent capable of prolonging APD and ERP in ventricular muscle and 
Purkinje fibers without altering the maximum upstroke velocity of the membrane action 
potential. The data suggest that UK-68,798 produces minimal effects on the ventricular 
conduction time, while prolonging the APD and increasing ventricular refractoriness. The 
electrophysiologic basis for the APD prolongation of UK-68,798 relates to inhibition of 
the time-independent , delayed rectifier current. Although the mechanism of the antifibril- 
latory action of UK-68,798 and other related class I11 antiarrhythmic agents may not be 
defined precisely, there are sufficient experimental data to suggest that this group of drugs 
possesses similar electrophysiologic properties and has similar effects on potassium con- 
ductance in ischemic myocardial tissue, suggesting that potassium channel antagonism is 
important. 
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